Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

IPRIVASK

DESIRUDIN RECOMBINANT

Standard Dose
15MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview IPRIVASK is listed in Drugs@FDA under application 021271 (BLA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DESIRUDIN RECOMBINANT Form and strength INJECTABLE;SUBCUTANEOUS - 15MG/VIAL Sponsor BAUSCH Submission history Latest submission status date: 2015-05-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview IPRIVASK is listed in Drugs@FDA under application 021271 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DESIRUDIN RECOMBINANT Form and strength INJECTABLE;SUBCUTANEOUS - 15MG/VIAL Sponsor BAUSCH Submission history Latest submission status date: 2015-05-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
IPRIVASK (DESIRUDIN RECOMBINANT) | Drug Monograph | MedicHelpline